MA30759B1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number
MA30759B1
MA30759B1 MA31652A MA31652A MA30759B1 MA 30759 B1 MA30759 B1 MA 30759B1 MA 31652 A MA31652 A MA 31652A MA 31652 A MA31652 A MA 31652A MA 30759 B1 MA30759 B1 MA 30759B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
fat
substance
oil
active ingredient
Prior art date
Application number
MA31652A
Other languages
English (en)
Inventor
Yukihiro Nomura
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30759B1 publication Critical patent/MA30759B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE SOLIDE CONTENANT UNE SUBSTANCE DE TYPE HUILE/CORPS GRAS À POINT DE FUSION BAS, DONT LA PROPRIÉTÉ D'ÉLUTION DE MÉDICAMENT EST AMÉLIORÉE ET QUI POSSÈDE D'EXCELLENTES PROPRIÉTÉS DE STABILITÉ ET DE DISSOLUTION. CETTE INVENTION CONCERNE PLUS SPÉCIFIQUEMENT UNE COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT UN PRINCIPE PHARMACOLOGIQUEMENT ACTIF, UNE SUBSTANCE DE TYPE DE HUILE/CORPS GRAS À POINT DE FUSION BAS ET UN LIANT DE FAIBLE VISCOSITÉ. CETTE INVENTION CONCERNE AUSSI UN PROCÉDÉ PERMETTANT D'AMÉLIORER L'ÉLUTION D'UN PRINCIPE PHARMACOLOGIQUEMENT ACTIF D'UNE COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT CE PRINCIPE PHARMACOLOGIQUEMENT ACTIF ET UNE SUBSTANCE DE TYPE HUILE/CORPS GRAS À POINT DE FUSION BAS, CARACTÉRISÉ PAR L'UTILISATION D'UN LIANT À FAIBLE VISCOSITÉ.
MA31652A 2006-08-10 2009-02-20 Composition pharmaceutique MA30759B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006218145 2006-08-10

Publications (1)

Publication Number Publication Date
MA30759B1 true MA30759B1 (fr) 2009-10-01

Family

ID=39033098

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31652A MA30759B1 (fr) 2006-08-10 2009-02-20 Composition pharmaceutique

Country Status (24)

Country Link
US (1) US20100016382A1 (fr)
EP (1) EP2058010B1 (fr)
JP (2) JP5361188B2 (fr)
KR (1) KR101464007B1 (fr)
CN (3) CN102813635A (fr)
AT (1) ATE555777T1 (fr)
AU (1) AU2007282400B2 (fr)
BR (1) BRPI0716030A2 (fr)
CA (1) CA2660427A1 (fr)
CO (1) CO6150195A2 (fr)
CR (1) CR10632A (fr)
EA (1) EA016728B1 (fr)
ES (1) ES2382902T3 (fr)
GE (1) GEP20125420B (fr)
IL (1) IL196853A0 (fr)
MA (1) MA30759B1 (fr)
MX (1) MX2009001429A (fr)
MY (1) MY147310A (fr)
NO (1) NO20090759L (fr)
NZ (1) NZ574954A (fr)
TN (1) TN2009000042A1 (fr)
UA (1) UA96302C2 (fr)
WO (1) WO2008018569A1 (fr)
ZA (1) ZA200901075B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006083A2 (fr) 2006-07-07 2008-01-10 Surmodics, Inc. Dispositif espaceur de plaie à billes
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
US9169238B2 (en) 2008-07-31 2015-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
KR101316653B1 (ko) * 2011-05-19 2013-10-10 한미정밀화학주식회사 헤테로고리 화합물의 제조방법
KR101275092B1 (ko) * 2011-05-19 2013-06-17 한미정밀화학주식회사 아질사르탄의 개선된 제조방법
CN103096878B (zh) * 2011-05-23 2015-06-17 江苏恒瑞医药股份有限公司 包含苯并咪唑衍生物的固体药物组合物
CN103113364B (zh) * 2012-08-27 2015-11-18 南京华威医药科技开发有限公司 阿齐沙坦多晶型的制备方法
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6895779B2 (ja) * 2017-03-17 2021-06-30 東和薬品株式会社 アジルサルタン含有固形医薬組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
IN201721047406A (fr) 2017-12-30 2020-06-19 Lupin Limited
WO2019246503A1 (fr) 2018-06-22 2019-12-26 Ideaz, Llc Comprimés de diphényle et leurs procédés de préparation
CN111617046A (zh) * 2020-07-09 2020-09-04 浙江诺得药业有限公司 阿齐沙坦分散片及其制备工艺
CN115531350B (zh) * 2022-11-03 2024-01-05 珠海润都制药股份有限公司 一种阿齐沙坦胶囊及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
CA2017916C (fr) * 1989-06-07 1999-02-02 Minoru Aoki Preparations a base d'etoposide
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
TW284688B (fr) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
CN1044088C (zh) * 1992-11-13 1999-07-14 武田药品工业株式会社 口服药物组合物及制备方法
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JPH1135451A (ja) * 1994-07-27 1999-02-09 Yamanouchi Pharmaceut Co Ltd 口腔内溶解型錠剤およびその製造方法
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
WO1999044590A1 (fr) * 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Preparation a liberation prolongee d'un antagoniste de l'aii, sa production, et son utilisation
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
JP2000053563A (ja) * 1998-08-07 2000-02-22 Bayer Yakuhin Ltd 苦味がマスクされた速放性細粒剤
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
WO2004067001A1 (fr) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Procede pour realiser une preparation enrobee
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP2006218145A (ja) 2005-02-14 2006-08-24 My Kk キャリーバッグ
ZA200711048B (en) * 2005-06-22 2009-05-27 Takeda Pharmaceutical Tablet containing hardly soluble active incredient

Also Published As

Publication number Publication date
CN102813635A (zh) 2012-12-12
MX2009001429A (es) 2009-02-17
NO20090759L (no) 2009-03-11
AU2007282400B2 (en) 2012-08-30
EP2058010B1 (fr) 2012-05-02
US20100016382A1 (en) 2010-01-21
WO2008018569A1 (fr) 2008-02-14
ZA200901075B (en) 2010-05-26
EA016728B1 (ru) 2012-07-30
EP2058010A1 (fr) 2009-05-13
CR10632A (es) 2009-04-14
KR20090050071A (ko) 2009-05-19
BRPI0716030A2 (pt) 2013-07-30
EP2058010A4 (fr) 2009-09-30
JP5361188B2 (ja) 2013-12-04
MY147310A (en) 2012-11-30
JPWO2008018569A1 (ja) 2010-01-07
TN2009000042A1 (en) 2010-08-19
JP2011168622A (ja) 2011-09-01
HK1133817A1 (en) 2010-04-09
NZ574954A (en) 2011-11-25
KR101464007B1 (ko) 2014-11-20
CO6150195A2 (es) 2010-04-20
UA96302C2 (en) 2011-10-25
GEP20125420B (en) 2012-03-26
EA200970188A1 (ru) 2009-08-28
AU2007282400A1 (en) 2008-02-14
ATE555777T1 (de) 2012-05-15
ES2382902T3 (es) 2012-06-14
CA2660427A1 (fr) 2008-02-14
IL196853A0 (en) 2009-11-18
CN103610673A (zh) 2014-03-05
CN101528262A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
EA200970188A1 (ru) Фармацевтическая композиция
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
FR2851470B1 (fr) Composition pharmaceutique pour administration transdermique ou transmuqueuse
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
ATE439123T1 (de) Verwendung von emulsionen zur intra- und periocularen injection
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
BRPI0507198A (pt) derivados de bisariluréia
EP1894567A4 (fr) Agents pharmaceutiques concomitants et leur utilisation
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
FR2867682B1 (fr) Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
WO2008081829A1 (fr) Copolymère de méthacrylate d'aminoalkyle e pour maintenir la solubilité d'un médicament faiblement soluble dans l'eau
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
ATE434431T1 (de) Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
WO2005041876A3 (fr) Formulations à base d'argiles résistantes au débordement
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
TW200616616A (en) Paclitaxel aqueous injection solution and methods for preparing the same
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
EP1460123A4 (fr) Procede servant a entretenir un arome et sa mise en application
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit